These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 11111019)

  • 1. Metabolism of glucagon by dipeptidyl peptidase IV (CD26).
    Pospisilik JA; Hinke SA; Pederson RA; Hoffmann T; Rosche F; Schlenzig D; Glund K; Heiser U; McIntosh CH; Demuth H
    Regul Pept; 2001 Jan; 96(3):133-41. PubMed ID: 11111019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide.
    Pauly RP; Demuth HU; Rosche F; Schmidt J; White HA; Lynn F; McIntosh CH; Pederson RA
    Metabolism; 1999 Mar; 48(3):385-9. PubMed ID: 10094118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach.
    Pauly RP; Rosche F; Wermann M; McIntosh CH; Pederson RA; Demuth HU
    J Biol Chem; 1996 Sep; 271(38):23222-9. PubMed ID: 8798518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
    Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
    Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.
    Hinke SA; Kühn-Wache K; Hoffmann T; Pederson RA; McIntosh CH; Demuth HU
    Biochem Biophys Res Commun; 2002 Mar; 291(5):1302-8. PubMed ID: 11883961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs.
    Hinke SA; Pospisilik JA; Demuth HU; Mannhart S; Kühn-Wache K; Hoffmann T; Nishimura E; Pederson RA; McIntosh CH
    J Biol Chem; 2000 Feb; 275(6):3827-34. PubMed ID: 10660533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
    Kieffer TJ; McIntosh CH; Pederson RA
    Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).
    Zhu L; Tamvakopoulos C; Xie D; Dragovic J; Shen X; Fenyk-Melody JE; Schmidt K; Bagchi A; Griffin PR; Thornberry NA; Sinha Roy R
    J Biol Chem; 2003 Jun; 278(25):22418-23. PubMed ID: 12690116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
    Pederson RA; White HA; Schlenzig D; Pauly RP; McIntosh CH; Demuth HU
    Diabetes; 1998 Aug; 47(8):1253-8. PubMed ID: 9703325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme.
    Bär J; Weber A; Hoffmann T; Stork J; Wermann M; Wagner L; Aust S; Gerhartz B; Demuth HU
    Biol Chem; 2003 Dec; 384(12):1553-63. PubMed ID: 14719797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
    Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
    Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
    Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
    Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
    Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
    Drucker DJ
    Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
    Demuth HU; McIntosh CH; Pederson RA
    Biochim Biophys Acta; 2005 Aug; 1751(1):33-44. PubMed ID: 15978877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.
    Plamboeck A; Holst JJ; Carr RD; Deacon CF
    Adv Exp Med Biol; 2003; 524():303-12. PubMed ID: 12675252
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of dipeptidyl peptidase IV (DP IV, CD26) activity abrogates stress-induced, cytokine-mediated murine abortions.
    Hildebrandt M; Arck PC; Kruber S; Demuth HU; Reutter W; Klapp BF
    Scand J Immunol; 2001 May; 53(5):449-54. PubMed ID: 11309152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of robotics to steady state enzyme kinetics: analysis of tight-binding inhibitors of dipeptidyl peptidase IV.
    Wang A; Huang Y; Taunk P; Magnin DR; Ghosh K; Robertson JG
    Anal Biochem; 2003 Oct; 321(2):157-66. PubMed ID: 14511679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.